Mostrar el registro sencillo del ítem

Artículo

dc.creatorRemón-Ruiz, Pabloes
dc.creatorVenegas-Moreno, Evaes
dc.creatorDios-Fuentes, Elenaes
dc.creatorCanelo Moreno, Juan Manueles
dc.creatorFernández Peña, Ignacioes
dc.creatorAlonso García, Miriames
dc.creatorSoto Moreno, Alfonso Manueles
dc.date.accessioned2022-09-20T18:27:36Z
dc.date.available2022-09-20T18:27:36Z
dc.date.issued2021
dc.identifier.citationRemón-Ruiz, P., Venegas-Moreno, E., Dios-Fuentes, E., Canelo Moreno, J.M., Fernández Peña, I., Alonso García, M. y Soto Moreno, A.M. (2021). A silent corticotroph pituitary carcinoma: lessons from an exceptional case. Frontiers in Endocrinology, 12, 1-9.
dc.identifier.issn1664-2392es
dc.identifier.urihttps://hdl.handle.net/11441/137243
dc.description.abstractNowadays, neither imaging nor pathology evaluation can accurately predict the aggressiveness or treatment resistance of pituitary tumors at diagnosis. However, histological examination can provide useful information that might alert clinicians about the nature of pituitary tumors. Here, we describe our experience with a silent corticothoph tumor with unusual pathology, aggressive local invasion and metastatic dissemination during follow-up. We present a 61-year-old man with third cranial nerve palsy at presentation due to invasive pituitary tumor. Subtotal surgical approach was performed with a diagnosis of silent corticotroph tumor but with unusual histological features (nuclear atypia, frequent multinucleation and mitotic figures, and Ki-67 labeling index up to 70%). After a rapid regrowth, a second surgical intervention achieved successful debulking. Temozolomide treatment followed by stereotactic fractionated radiotherapy associated with temozolomide successfully managed the primary tumor. However, sacral metástasis showed up 6 months after radiotherapy treatment. Due to aggressive distant behavior, a carboplatine-etoposide scheme was decided but the patient died of urinary sepsis 31 months after the first symptoms. Our case report shows how the presentation of a pituitary tumor with aggressive features should raise a suspicion of malignancy and theneed of follow up by multidisciplinary team with experience in its management. Metastases may occur even if the primary tumor is well controlled.es
dc.formatapplication/pdfes
dc.format.extent9 p.es
dc.language.isoenges
dc.publisherFrontiers Research Foundationes
dc.relation.ispartofFrontiers in Endocrinology, 12, 1-9.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectPituitary tumores
dc.subjectSilent corticothoph tumores
dc.subjectPituitary carcinomaes
dc.subjectRadiotherapyes
dc.titleA silent corticotroph pituitary carcinoma: lessons from an exceptional casees
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.relation.publisherversionhttps://www.frontiersin.org/articles/10.3389/fendo.2021.784889/fulles
dc.identifier.doi10.3389/fendo.2021.784889es
dc.journaltitleFrontiers in Endocrinologyes
dc.publication.volumen12es
dc.publication.initialPage1es
dc.publication.endPage9es

FicherosTamañoFormatoVerDescripción
290.pdf50.14MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional